Ocular Therapeutix (NASDAQ:OCUL) Stock Rating Cut to Strong Sell at Wall Street Zen

Wall Street Zen lowered shares of Ocular Therapeutix (NASDAQ:OCUL) from a hold rating to a strong sell rating in a research report released on Saturday,Wall Street Zen reports.

Other equities research analysts have also issued research reports about the company. Needham & Company LLC reiterated a “buy” rating and set a $18.00 target price on shares of Ocular Therapeutix in a research report on Monday, October 19th. UBS Group started coverage on Ocular Therapeutix in a report on Sunday, October 11th. They issued a “buy” rating and a $14.00 target price for the company. Chardan Capital restated a “buy” rating and set a $23.00 target price on shares of Ocular Therapeutix in a research report on Friday, October 2nd. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a research note on Tuesday, September 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $23.83.

Ocular Therapeutix Stock Performance

NASDAQ:OCUL traded down $0.07 during trading hours on Friday, reaching $6.21. 2,487,177 shares of the company’s stock were exchanged, compared to its average volume of 2,785,207. Ocular Therapeutix has a 1-year low of $5.99 and a 1-year high of $16.44. The company has a quick ratio of 13.03, a current ratio of 9.12 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of -4.25 and a beta of 1.22. The company has a 50-day moving average of $7.99 and a 200 day moving average of $8.91.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.06). The business had revenue of $12.87 million during the quarter, compared to analysts’ expectations of $14.27 million. Ocular Therapeutix had a negative net margin of 648.64% and a negative return on equity of 59.95%. During the same period in the previous year, the company posted ($0.38) earnings per share. Ocular Therapeutix’s quarterly revenue was down 11.5% on a year-over-year basis. Research analysts anticipate that Ocular Therapeutix will post -1.61 EPS for the current year.

Insiders Place Their Bets

In other news, insider Peter Kaiser sold 9,990 shares of Ocular Therapeutix stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $7.05, for a total transaction of $70,429.50. Following the completion of the transaction, the insider owned 254,388 shares of the company’s stock, valued at $1,793,435.40. The trade was a 3.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Jeffrey Heier sold 10,869 shares of the business’s stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $7.05, for a total transaction of $76,626.45. Following the completion of the sale, the insider owned 307,457 shares in the company, valued at $2,167,571.85. This represents a 3.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 98,090 shares of company stock valued at $787,920. Company insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Commonwealth Equity Services LLC boosted its position in Ocular Therapeutix by 8.1% during the 3rd quarter. Commonwealth Equity Services LLC now owns 20,992 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 1,575 shares during the period. Principal Financial Group Inc. increased its holdings in shares of Ocular Therapeutix by 24.1% in the 1st quarter. Principal Financial Group Inc. now owns 13,623 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 2,642 shares during the period. NewEdge Advisors LLC lifted its position in Ocular Therapeutix by 21.7% in the 2nd quarter. NewEdge Advisors LLC now owns 16,725 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 2,979 shares during the last quarter. Raiffeisen Bank International AG lifted its position in Ocular Therapeutix by 5.3% in the 2nd quarter. Raiffeisen Bank International AG now owns 100,000 shares of the biopharmaceutical company’s stock valued at $990,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new position in Ocular Therapeutix during the 2nd quarter valued at about $51,000. 59.21% of the stock is owned by hedge funds and other institutional investors.

Ocular Therapeutix News Roundup

Here’s some of the latest news about OCUL:

• Positive Sentiment: A report highlights Ocular Therapeutix’s Phase 3 wet age-related macular degeneration (AMD) success, a potentially important clinical milestone. How Investors Are Reacting To Ocular Therapeutix (OCUL) Phase 3 Wet AMD Success
• Positive Sentiment: HC Wainwright raised its price target to $28 and retained a Buy rating; RBC Capital also kept its Buy rating, signaling continued analyst optimism. Ocular Therapeutix Stock Gets Price Target Increase from HC Wainwright RBC Capital Keeps Their Buy Rating
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across multiple quarters and for FY2026 and FY2027. Its FY2027 loss estimate widened from $1.54 to $1.87 per share, suggesting expectations for near-term profitability have weakened despite the Buy rating.

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time. Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.